A5026290406- Hepatitis B Virus Studies
- Hepatitis C virus research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Liver Disease Diagnosis and Treatment
- Viral Infections and Immunology Research
- Hepatitis Viruses Studies and Epidemiology
- RNA Research and Splicing
- HIV/AIDS drug development and treatment
- Animal Disease Management and Epidemiology
- SARS-CoV-2 detection and testing
- RNA and protein synthesis mechanisms
- RNA regulation and disease
- Long-Term Effects of COVID-19
- Viral gastroenteritis research and epidemiology
- T-cell and Retrovirus Studies
- Animal Virus Infections Studies
- Respiratory viral infections research
- Animal Genetics and Reproduction
- Heparin-Induced Thrombocytopenia and Thrombosis
- Milk Quality and Mastitis in Dairy Cows
- Bacterial Identification and Susceptibility Testing
- Influenza Virus Research Studies
- Peptidase Inhibition and Analysis
- Viral Infections and Outbreaks Research
VIR Biotechnology (United States)
2020-2024
Beijing Ditan Hospital
2022
Capital Medical University
2022
Gilead Sciences (United States)
2016-2019
University of California, Irvine
2012-2016
National Institute of Allergy and Infectious Diseases
2015
National Institutes of Health
2015
Département Santé Animale
1979-1984
BackgroundCoronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 high-risk early the course disease.MethodsIn this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, 1:1 ratio, nonhospitalized symptomatic (≤5 days after onset symptoms) at least one risk factor for receive single...
Antibody-dependent enhancement (ADE) of disease is a general concern for the development vaccines and antibody therapies because mechanisms that underlie protection against any virus have theoretical potential to amplify infection or trigger harmful immunopathology. This possibility requires careful consideration at this critical point in pandemic coronavirus 2019 (COVID-19), which caused by severe acute respiratory syndrome 2 (SARS-CoV-2). Here we review observations relevant risks ADE...
Older patients and those with comorbidities who are infected SARS-CoV-2 may be at increased risk of hospitalization death. Sotrovimab is a neutralizing antibody for the treatment high-risk to prevent COVID-19 progression.To evaluate efficacy adverse events sotrovimab in preventing progression mild moderate severe disease.Randomized clinical trial including 1057 nonhospitalized symptomatic, least 1 factor conducted 57 sites Brazil, Canada, Peru, Spain, US from August 27, 2020, through March...
ABSTRACT Sotrovimab (VIR-7831) and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). were derived from a parent antibody (S309) isolated memory B cells 2003 (SARS-CoV) survivor. Both mAbs contain an “LS” mutation in Fc region to prolong serum half-life. In addition, encodes GAALIE that has been shown previously evoke CD8+ T-cells context vivo viral infection. neutralize wild-type variant...
Background & Aims Current treatment for chronic hepatitis B virus (cHBV) infection requires lifelong treatment. New therapy aimed towards HBV functional cure would represent a clinically meaningful advancement. ALN-HBV and VIR-2218 (modified from by Enhanced Stabilization Chemistry Plus technology reducing off-target, seed-mediated binding while maintaining on-target antiviral activity) are investigational RNAi therapeutics that target all major transcripts. Methods We report the safety of...
Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF up 10 years in well-described cohort CHB patients.Hepatitis e antigen (HBeAg)-negative HBeAg-positive patients from two randomised, double-blind trials (ClinicalTrials.gov: NCT00117676 NCT00116805) completed 48 weeks randomised with or adefovir dipivoxil. A subset these was then eligible receive open-label years. At Year 10, were assessed...
Summary A major hurdle in the long‐term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression absence drug resistance. To date, no evidence resistance tenofovir disoproxil fumarate (TDF) has been observed. cumulative evaluation CHB who qualified for surveillance over 8 years TDF was conducted. Patients studies GS‐US‐174‐0102 (HBeAg−) and GS‐US‐174‐0103 (HBeAg+) were randomized 2:1 receive or adefovir dipivoxil (ADV) 48 weeks followed by open‐label through year 8....
Influenza virus infections are a global public health problem, with significant impact of morbidity and mortality from both annual epidemics pandemics. The current strategy for preventing influenza is to develop new vaccine each year against specific circulating strains. Because these vaccines unlikely protect an antigenically divergent strain or pandemic novel hemagglutinin (HA) subtype, there critical need that all A viruses, so-called "universal" vaccine. Here we show mice were broadly...
Vesatolimod is an oral agonist of toll-like receptor 7 designed to minimize systemic exposure and side effects. We assessed the safety efficacy vesatolimod in viremic chronic hepatitis B (CHB) patients not currently on antiviral treatment (OAV) a phase 2, multicentre, double-blind, randomized, placebo-controlled study. A total 192 stratified by HBeAg status alanine aminotransferase level were randomized 2:2:2:1 receive (1-, 2- or 4-mg) placebo once weekly for 12 weeks; tenofovir disoproxil...
Abstract Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization and death older patients those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody designed to treat such high-risk early the course of disease, thereby preventing Covid-19 progression. Methods In this ongoing, multicenter, double-blind, phase 3 trial, nonhospitalized symptomatic at least one risk factor for progression were randomized (1:1) an intravenous...
Chronic hepatitis B is a global public health problem, and coinfection with delta virus (HDV) worsens disease outcome. Here, we describe (HBV) surface antigen (HBsAg)-targeting monoclonal antibody (mAb) the potential to treat chronic D.HBsAg-specific mAbs were isolated from memory cells of HBV vaccinated individuals. In vitro neutralization was determined against HDV enveloped HBsAg representing eight genotypes. Human liver-chimeric mice treated twice weekly candidate mAb starting 3 weeks...
ABSTRACT To successfully complete their replication cycles, picornaviruses modify several host proteins to alter the cellular environment favor virus production. One such target of viral proteinase cleavage is AU-rich binding factor 1 (AUF1), a protein that binds elements, or AREs, in 3′ noncoding regions (NCRs) mRNAs affect stability RNA. Previous studies found that, during poliovirus human rhinovirus infection, AUF1 cleaved by 3CD and can interact with long 5′ NCR these viruses vitro ....
Due to the limited coding capacity of picornavirus genomic RNAs, host RNA binding proteins play essential roles during viral translation and replication. Here we describe experiments suggesting that AUF1, a protein involved in mRNA decay, plays role infectious cycle picornaviruses such as poliovirus human rhinovirus. We observed cleavage AUF1 or rhinovirus infection, well interaction this with 5' noncoding regions these genomes. Additionally, proteinase 3CD, encoded by was shown cleave all...
Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF). However, limited data are available its resistance profiles. In two clinical trials, 1,298 E antigen-positive -negative CHB were randomized 2:1 treated TAF (n = 866) or TDF 432). Baseline nucleos(t)ide analog substitutions in HBV polymerase/reverse transcriptase (Pol/RT) assessed using INNO-LiPA Multi-DR v2/v3....
Infection of mammalian cells by picornaviruses results in the nucleocytoplasmic redistribution certain host cell proteins. These viruses interfere with import-export pathways, allowing for cytoplasmic accumulation nuclear proteins that are then available to function viral processes. We recently described relocalization cellular splicing factor SRp20 during poliovirus infection. is an important internal ribosome entry site (IRES) trans-acting (ITAF) IRES-mediated translation; however, it not...
Abstract Background COVID-19 disproportionately results in hospitalization and death older patients those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody that binds highly conserved epitope of the SARS-CoV-2 receptor binding domain has an Fc modification increases half-life. retains activity against UK, S. Africa, Brazil, India, New York California variants vitro. Objectives To evaluate efficacy safety treatment sotrovimab high-risk, non-hospitalized...
An enzyme-linked immunosorbent assay (ELISA) was developed for the detection of antibodies to caprine arthritis encephalitis virus (CAEV) in goat sera. The system evaluated using some 1500 sera from flocks known clinical history. From this data interpretation limits were determined. ELISA compared with a gel precipitin test 5800 Of positive sera, detected 97.3% and AGPT 61%. Further evaluation made 60 CAEV reactivity USA, results agreed 100%. Indications are that antibody envelope...
Abstract Importance Older patients and those with underlying comorbidities infected SARS-CoV-2 may be at increased risk of hospitalization death from COVID-19. Sotrovimab is a neutralizing antibody designed for treatment high-risk to prevent COVID-19 progression. Objective To evaluate the efficacy safety sotrovimab in preventing progression mild moderate severe disease. Design Randomized, double-blind, multicenter, placebo-controlled, phase 3 study. Setting 57 centers 5 countries....
During infection by picornaviruses, the cellular environment is modified to favour virus replication. This includes modification of specific host proteins, including recently discovered viral proteinase cleavage mRNA decay factor AU-rich binding 1 (AUF1). RNA-binding protein was shown previously act as a restriction during poliovirus, rhinovirus and coxsackievirus infection. these viruses, AUF1 relocalizes cytoplasm cleaved 3C/3CD proteinase. In this study, we demonstrated that replication...